This makes it challenging to pursue an NOS‐targeting strategy in cancer patients.[14] Another concern with targeting NOS is the possible off‐target consequences related to the application of pan NOS inhibitors, which may cause hypertension or impaired cardiac function.[14] Therefore, further investigation is needed to ensure the accurate and safe utilization of NOS inhibitors as a potential NOS‐targeting cancer treatment. The gene discussed is NOS2; the disease is hypertensive disorder.